ACCREDITATION STATEMENT
The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Endocrine Society has achieved Accreditation with Commendation.
The Endocrine Society designates this activity for a maximum of 29 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
STATEMENT OF INDEPENDENCE
As a provider of continuing medical education (CME) accredited by the Accreditation Council for Continuing Medical Education, The Endocrine Society has a policy ensuring that the content and the quality of this educational program are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of The Endocrine Society's Clinical Endocrinology Update (CEU) Steering Committee.
DISCLAIMER
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society.
LEARNING OBJECTIVES
Upon completion of this activity, learners will be able to:
Discuss state-of-the-art research in endocrinology
Demonstrate updated knowledge of the diagnosis and treatment of diabetes, lipid, osteoporosis, pituitary, adrenal, thyroid, and reproductive endocrine disorders
Employ enhanced skills and practiceknowledge and clinical skills in improving patient care
TARGET AUDIENCE
This continuing medical education activity should be of substantial interest to endocrinologists, endocrine fellows, internists, healthcare professionals who treat endocrine disorders, and others seeking an update in recent developments in the treatment of endocrine disorders.
DISCLOSURE POLICY
The faculty, committee members, and staff involved in planning this CME activity are required to disclose to learners any relevant financial relationship(s) that have occurred within the last 12 months with any commercial interest(s) whose products or services are discussed in the CME content. Such relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent faculty with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments. It remains for learners to determine whether financial interests or relationships may influence the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships:
Beverly MK Biller, MD has received research grants from Novartis and Pfizer for her role as Principal Investigator, and has received consulting fees from Novartis and Pfizer.
John B Buse, MD, PhD has disclosed that he has received indirect benefit, through funds paid to accounts under the control of the University of North Carolina School of Medicine�s Division of Endocrinology, for his services as an investigator, consultant, and/or speaker, from the following companies: Amylin, Bayhill Therapeutics, BD Research Laboratories, Bristol-Myers Squibb, Dexcom, Eli Lilly, GSK, Hoffman-La Roche, Intekrin, Intuity Medical, Johnson & Johnson, MannKind, Medtronic, Merck, MicroIslet, Novartis, NovoNordisk, Osiris, Pfizer, sanofi-aventis, Transition Therapeutics, and Wyeth. He also disclosed that he is a shareholder of Insulet.
David M Cook, MD has received speaker honoraria from Eli Lilly and Novo Nordisk and received research support from Indeus.
Marjorie Luckey, MD has received speaker honoraria from Novartis; has received honoraria from Eli Lilly for her role as consultant and speaker; has received consulting fees from Amgen and Wyeth; has received speaker honoraria and research grant support from sanofi-aventis and Proctor & Gamble.
Michael R McClung, MD has received research grant support from Amgen, Lilly, Merck, Novartis, and Proctor & Gamble for his role as Principal Investigator; has received consulting fees from Amgen, Lilly, Merck and Novartis; has received speaker honoraria from Lilly, Novartis, and sanofi-aventis.
Paul D Miller, MD has received research grant support from Amgen, Merck, Lilly, Novartis, Roche-GSK, and the Alliance for Better Bone Health; has served on scientific advisory boards for Amgen, Lilly, Novartis, and the Alliance for Better Bone Health; has served on speakers' bureaus for Amgen, Lilly, Novartis, Roche-GSK, and the Alliance for Better Bone Health.
Mark E Molitch, MD has received research grant support from Eli Lilly for serving as investigator.
Nanette F Santoro, MD has received consulting fees from Radius Health and QuatRx.
Leonard Wartofsky, MACP, MD has received speaker honoraria from Genzyme.
Nelson B Watts, MD has received honoraria for lectures from Amgen, Novartis, Procter & Gamble, and sanofi-aventis; has received consulting fees from Amgen, Eli Lilly, Novartis, Novo Nordisk, Proctor & Gamble and sanofi-aventis; has received research grant support from Amgen, Eli Lilly, Novartis and Proctor & Gamble.
Holly R Wyatt, MD has received consulting fees from Arena Pharmaceuticals for her role as advisory board member; has received consulting fees from Nutrisystems and GSK; has received speaker honoraria from Amgen; has received research grant/clinical trial support from Pfizer and Orexigen for her role as Principal Investigator.
The following faculty reported NO relevant financial relationships:
Erik K Alexander, MD; Bradley D Anawalt, MD; Laura K Bachrach, MD; Rebecca S Bahn, MS, MD; Mark D DeBoer, MD; David A Ehrmann, MD; Whitney S Goldner, MD; Boyd E Metzger, MD; R Harsha Rao, MD, MRCP; Matthew D Ringel, MD; Janet A Schlechte, MS, MD; Lisa R Tannock, MD.
The following CEU Steering Committee members who planned and/or reviewed content for this activity reported relevant financial relationships:
Steven T Harris, MD, FACP has served as a speaker for Eli Lilly & Company, GSK, Novartis, Procter & Gamble Pharmaceuticals, Roche, sanofi-aventis, and Wyeth; has served as a consultant for Amgen, Eli Lilly & Company, GSK, Merck & Company, Novartis, Procter & Gamble, Roche, sanofi-aventis, and Wyeth.
The following CEU Steering Committee members who planned and/or reviewed content for this activity reported NO relevant financial relationships:
Steven P Hodak, MD; Jennifer L Larsen, MD; Kathryn A Martin, MD; Janet A Schlechte, MD.
The Endocrine Society staff associated with the development of the content for this activity reported NO relevant financial relationships.
CONFLICT OF INTEREST STATEMENT
The scientific content of this activity was developed by The Endocrine Society's CEU Steering Committee, independent of grant support and in accordance with the ACCME's Essential Areas and Elements, including the Standards for Commercial Support. The commercial supporters of this meeting have no influence over topics or speakers.
POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation.
Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY & CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
This activity is not supported by grants, other funds, or in-kind contributions from commercial supporters.
METHOD OF PARTICIPATION
This enduring material is presented in an online/computer-based format. System requirements include:
For Windows, Firefox 1.5 or Internet Explorer 6.0 with Flash 8 or better installed.
For Macintosh OS X, Safari 2.0 or Firefox 1.5 with Flash 8 or better installed.
The estimated time to complete this activity, including review of material, is 29 hours.
To receive AMA PRA Category 1 CreditsTM, the learner should:
Select a session and listen to the audio and/or view the slides.
Complete the evaluation provided at the end of the session and click on "submit" to add the session to the learner's transcript. The transcript will appear and the learner will have the option of printing a CME certificate then or at a later time, after viewing multiple sessions.
Select additional sessions and proceed as directed above, to accumulate credits for participating in multiple sessions.
Credits awarded correspond to the length of time for each session, which varies from 0.5 to 1 hour.
Last Review Date: October 11, 2009
Activity Release Date: November 30, 2009
Activity Expiration Date: November 30, 2010
For technical assistance or information, please contact call 972-910-6899 (9:00 AM to 5:00 PM EST) or E-mail: multiviewMediaSupport@multiview.com.
For questions regarding CME content or obtaining CME credit, please contact The Endocrine Society at 301.941.0200 or education@endo-society.org.
|